140 related articles for article (PubMed ID: 9381994)
1. Comparison of bezafibrate versus lovastatin for lowering plasma insulin, fibrinogen, and plasminogen activator inhibitor-1 concentrations in hyperlipemic heart transplant patients.
Zambrana JL; Velasco F; Castro P; Concha M; Vallés F; Montilla P; Jimenéz-Perepérez JA; López-Miranda J; Pérez-Jiménez F
Am J Cardiol; 1997 Oct; 80(7):836-40. PubMed ID: 9381994
[TBL] [Abstract][Full Text] [Related]
2. Bezafibrate and lovastatin decrease the oxidizability of low-density lipoproteins in heart transplant recipients with hyperlidemia.
Zambrana JL; López-Miranda J; Blanco A; Arizón JM; Jansen S; Paniagua JA; Jimenéz-Perepérez JA; Concha M; Pérez-Jiménez F
J Heart Lung Transplant; 1998 Dec; 17(12):1213-9. PubMed ID: 9883763
[TBL] [Abstract][Full Text] [Related]
3. [A comparison of bezafibrate and lovastatin treatment at the usual doses in post-heart transplant hyperlipemia].
Zambrana García JL; López Miranda J; Anguita Sánchez M; Blanco Cerrada J; Vallés Belsúe F; Casares Mediavilla J; Muñoz Carvajal I; Jiménez Perepérez JA; Pérez Jiménez F
Rev Esp Cardiol; 1996 Dec; 49(12):892-8. PubMed ID: 9026840
[TBL] [Abstract][Full Text] [Related]
4. Effect of bezafibrate on hypercoagulability assessed by fluorogenic prothrombin time in hyperlipidemic patients with non-insulin-dependent diabetes mellitus.
Yoshinari M; Yamamoto M; Waklsaka M; Iwase M; Takano K; Fujishlma M
Thromb Res; 1997 Jun; 86(6):443-51. PubMed ID: 9219324
[TBL] [Abstract][Full Text] [Related]
5. Lovastatin versus bezafibrate for hyperlipemia treatment after heart transplantation.
Hidalgo L; Zambrana JL; Blanco-Molina A; López-Granados A; Concha M; Casares J; Jiménez-Pérez J; López-Miranda J; Pérez-Jiménez F
J Heart Lung Transplant; 1995; 14(3):461-7. PubMed ID: 7654731
[TBL] [Abstract][Full Text] [Related]
6. Atherogenic risk reduction in patients with dyslipidaemia. comparison between bezafibrate and lovastatin.
Sinzinger H; Pirich C; Kondor P; Etti H
Eur Heart J; 1995 Nov; 16(11):1491-501. PubMed ID: 8881840
[TBL] [Abstract][Full Text] [Related]
7. Comparison of lovastatin and bezafibrate on lipoprotein(a) plasma levels in cardiac transplant recipients.
Perez-Jimenez F; Hidalgo L; Zambrana JL; Arizon JM; Jimenez-Pereperez JA; Concha M; Espino A; Blanco J; Valles F; Lopez-Miranda J
Am J Cardiol; 1995 Mar; 75(8):648-50. PubMed ID: 7887403
[TBL] [Abstract][Full Text] [Related]
8. Bezafibrate. An update of its pharmacology and use in the management of dyslipidaemia.
Goa KL; Barradell LB; Plosker GL
Drugs; 1996 Nov; 52(5):725-53. PubMed ID: 9118820
[TBL] [Abstract][Full Text] [Related]
9. A randomized pilot trial of low-dose combination lipid-lowering therapy following coronary artery bypass grafting.
Barbir M; Hunt BJ; Galloway D; Taylor A; Ilsley C; Mitchell A; Yacoub M
Clin Cardiol; 1994 Feb; 17(2):59-64. PubMed ID: 8162627
[TBL] [Abstract][Full Text] [Related]
10. Comparison of bezafibrate and simvastatin in the treatment of dyslipidaemia in patients with NIDDM.
Jeck T; Riesen WF; Keller U
Diabet Med; 1997 Jul; 14(7):564-70. PubMed ID: 9223394
[TBL] [Abstract][Full Text] [Related]
11. Maxepa versus bezafibrate in hyperlipidemic cardiac transplant recipients.
Barbir M; Hunt B; Kushwaha S; Kehely A; Prescot R; Thompson GR; Mitchell A; Yacoub M
Am J Cardiol; 1992 Dec; 70(20):1596-601. PubMed ID: 1466329
[TBL] [Abstract][Full Text] [Related]
12. Bezafibrate improves hypertension and insulin sensitivity in humans.
Kim JI; Tsujino T; Fujioka Y; Saito K; Yokoyama M
Hypertens Res; 2003 Apr; 26(4):307-13. PubMed ID: 12733699
[TBL] [Abstract][Full Text] [Related]
13. Plasma levels of tissue plasminogen activator and plasminogen activator inhibitor-1 are correlated with the presence of transplant coronary artery disease in cardiac transplant recipients.
Warshofsky MK; Wasserman HS; Wang W; Teng P; Sciacca R; Apfelbaum M; Schwartz A; Michler RE; Mancini DM; Cannon PJ; Rabbani LE
Am J Cardiol; 1997 Jul; 80(2):145-9. PubMed ID: 9230149
[TBL] [Abstract][Full Text] [Related]
14. Efficacy, safety and tolerability of lovastatin and bezafibrate retard in patients with hypercholesterolemia.
Schumacher M; Eber B; Silberbauer K; Breier C; Stühlinger W; Schmidt P; Gaul G; Klein W
Acta Med Austriaca; 1992; 19(5):140-4. PubMed ID: 1298143
[TBL] [Abstract][Full Text] [Related]
15. The effect of simvastatin and bezafibrate on bile composition and gall-bladder emptying in female non-insulin-dependent diabetics.
Wilson IR; Hurrell MA; Pattinson NR; Chapman BA
J Gastroenterol Hepatol; 1994; 9(5):447-51. PubMed ID: 7827294
[TBL] [Abstract][Full Text] [Related]
16. Effect of three fibrate derivatives and of two HMG-CoA reductase inhibitors on plasma fibrinogen level in patients with primary hypercholesterolemia.
Branchi A; Rovellini A; Sommariva D; Gugliandolo AG; Fasoli A
Thromb Haemost; 1993 Aug; 70(2):241-3. PubMed ID: 8236126
[TBL] [Abstract][Full Text] [Related]
17. Severe hypertriglyceridemia with insulin resistance is associated with systemic inflammation: reversal with bezafibrate therapy in a randomized controlled trial.
Jonkers IJ; Mohrschladt MF; Westendorp RG; van der Laarse A; Smelt AH
Am J Med; 2002 Mar; 112(4):275-80. PubMed ID: 11893366
[TBL] [Abstract][Full Text] [Related]
18. Effects of fluvastatin and bezafibrate combination on plasma fibrinogen, t-plasminogen activator inhibitor and C reactive protein levels in coronary artery disease patients with mixed hyperlipidaemia (FACT Study)--a rebuttal.
Hirschfield G
Thromb Haemost; 2001 Jan; 85(1):189-90. PubMed ID: 11204580
[No Abstract] [Full Text] [Related]
19. Effects of fluvastatin and bezafibrate combination on plasma fibrinogen, t-plasminogen activator inhibitor and C reactive protein levels in coronary artery disease patients with mixed hyperlipidaemia (FACT study). Fluvastatin Alone and in Combination Treatment.
Cortellaro M; Cofrancesco E; Boschetti C; Cortellaro F; Mancini M; Mariani M; Paoletti R
Thromb Haemost; 2000 Apr; 83(4):549-53. PubMed ID: 10780315
[TBL] [Abstract][Full Text] [Related]
20. Lovastatin versus bezafibrate: efficacy, tolerability, and effect on urinary mevalonate.
Beil FU; Schrameyer-Wernecke A; Beisiegel U; Greten H; Karkas JD; Liou R; Alberts AW; Eckardt HG; Till AE
Cardiology; 1990; 77 Suppl 4():22-32. PubMed ID: 2073669
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
